tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Mite Infestations D008924 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Digestive System Diseases D004066 3 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Stienstra NA et al. Development of a Simple and Rapid Method to Measure the Free Fraction of Tacrolimus in Plasma Using Ultrafiltration and LC-MS/MS. 2016 Ther Drug Monit pmid:27805928
Prytula A et al. Tacrolimus Predose Concentration Is Associated With Hypertension in Pediatric Liver Transplant Recipients. 2016 J. Pediatr. Gastroenterol. Nutr. pmid:26910645
Muduma G et al. Indirect treatment comparison of belatacept versus tacrolimus from a systematic review of immunosuppressive therapies for kidney transplant patients. 2016 Curr Med Res Opin pmid:26907083
Sato Y et al. Acute encephalitis with refractory, repetitive partial seizures: Pathological findings and a new therapeutic approach using tacrolimus. 2016 Brain Dev. pmid:26906012
Fu LF et al. Improvement of FK506 production by synthetic biology approaches. 2016 Biotechnol. Lett. pmid:27600954
Rodrigo E et al. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development. 2016 Transplantation pmid:26703349
Hellström VC et al. Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study. 2016 Acta Oncol pmid:26824275
Gathogo E et al. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients. 2016 Transplantation pmid:26413990
Snell GI et al. ABO incompatible renal transplantation following lung transplantation. 2016 Transpl. Immunol. pmid:27663090
Juillerat A et al. Design of chimeric antigen receptors with integrated controllable transient functions. 2016 Sci Rep pmid:26750734
Prakash A et al. Crystal structure of the FK506 binding domain of human FKBP25 in complex with FK506. 2016 Protein Sci. pmid:26749369
Bae JM et al. Repigmentation of poliosis in a patient with segmental vitiligo. 2016 J. Am. Acad. Dermatol. pmid:27317537
Ganetsky A et al. Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. 2016 Bone Marrow Transplant. pmid:26691423
El-Asmar J et al. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. 2016 Hematol Oncol Stem Cell Ther pmid:26684920
Gojowy D et al. High Frequency of Arterial Hypertension in Patients After Liver Transplantation. 2016 Transplant. Proc. pmid:27496479
Wilusz M et al. Effects of Immunosuppressive Drugs on Serum Fatty Acids of Phospholipids Fraction in Renal Transplant Recipients. 2016 Transplant. Proc. pmid:27496457
Mehraj V et al. The Dynamic Role of the IL-33/ST2 Axis in Chronic Viral-infections: Alarming and Adjuvanting the Immune Response. 2016 EBioMedicine pmid:27397514
Wu Q et al. Repair of Neurological Function in Response to FK506 Through CaN/NFATc1 Pathway Following Traumatic Brain Injury in Rats. 2016 Neurochem. Res. pmid:27386875
O'Donnell JC et al. Transient Oxygen/Glucose Deprivation Causes a Delayed Loss of Mitochondria and Increases Spontaneous Calcium Signaling in Astrocytic Processes. 2016 J. Neurosci. pmid:27383588
Mittal A et al. Pilot Study to Evaluate the Efficacy and Safety of Oral Tacrolimus in Adult Patients With Refractory Severe Plaque Psoriasis. 2016 J Cutan Med Surg pmid:26553734
Roblin E et al. Lipid profile and cardiovascular risk factors in pediatric liver transplant recipients. 2016 Pediatr Transplant pmid:26750745
Zarrinpar A et al. Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform. 2016 Sci Transl Med pmid:27053773
Deininger KM et al. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients. 2016 Clin Transplant pmid:27314545
de Mesquita Coutinho PR et al. Effects of tacrolimus and erythropoietin in experimental spinal cord lesion in rats: functional and histological evaluation. 2016 Spinal Cord pmid:26481712
M Kotowski M et al. The influence of the tumor necrosis factor-alpa-308G>A polymorphism on the efficacy of immunosuppressive therapy in patients after kidney transplantation. 2016 J. Physiol. Pharmacol. pmid:28195062
Kyaw TH et al. A 45-Year-Old Woman With 3 Weeks of Cough and Night Sweats. 2016 Chest pmid:26965979
Golubovic B et al. Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients. 2016 Curr. Med. Chem. pmid:26687831
Yousef AM et al. Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients. 2016 Iran J Kidney Dis pmid:27225724
Fields JA et al. Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity. 2016 J Neuroinflammation pmid:27220536
Jia W et al. The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms. 2016 BMC Microbiol. pmid:27316338
Azzi J et al. Targeted Delivery of Immunomodulators to Lymph Nodes. 2016 Cell Rep pmid:27134176
SelimoÄŸlu MA et al. Evaluation of renal functions in pediatric liver transplantation. 2016 Pediatr Transplant pmid:26607307
Giussani A et al. Posterior reversible encephalopathy syndrome after kidney transplantation in pediatric recipients: Two cases. 2016 Pediatr Transplant pmid:26607205
Adler M et al. A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. 2016 J. Am. Soc. Nephrol. pmid:26260164
Labroo P et al. Controlled Delivery of FK506 to Improve Nerve Regeneration. 2016 Shock pmid:27058050
Kawahara T et al. Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis. 2016 Mol. Carcinog. pmid:25594762
Brito-Costa A et al. Factors Associated With Changes in Body Composition Shortly After Orthotopic Liver Transplantation: The Potential Influence of Immunosuppressive Agents. 2016 Transplantation pmid:27136260
Sinangil A et al. New-Onset Diabetes After Kidney Transplantation and Pretransplant Hypomagnesemia. 2016 Prog Transplant pmid:27136250
Moiseev IS et al. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil. 2016 Biol. Blood Marrow Transplant. pmid:26970381
Dury S et al. Bronchiectasis diagnosed after renal transplantation: a retrospective multicenter study. 2015 BMC Pulm Med pmid:26545860
Obayashi N et al. Management of tacrolimus-associated food allergy after liver transplantation. 2015 Pediatr Int pmid:26541649
Kwon M et al. Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. 2015 Arch. Pharm. Res. pmid:24627339
Tang T et al. Roles of the tacrolimus-dependent transcription factor IRF4 in acute rejection after liver transplantation. 2015 Int. Immunopharmacol. pmid:26093273
Hu L et al. Severe Tacrolimus-Induced Granulomatous Rosacea Recalcitrant to Oral Tetracyclines. 2015 J Drugs Dermatol pmid:26091390
Melilli E et al. De novo use of a generic formulation of tacrolimus versus reference tacrolimus in kidney transplantation: evaluation of the clinical results, histology in protocol biopsies, and immunological monitoring. 2015 Transpl. Int. pmid:26088437
Miura M et al. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts. 2015 Nephrology (Carlton) pmid:26031588
Yagisawa T et al. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity. 2015 Nephrology (Carlton) pmid:26031587
Lee J et al. A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk. 2015 J. Korean Med. Sci. pmid:26028917
Huang G et al. [Analysis on BK virus associated nephropathy related risk factors in renal transplant recipients]. 2015 Zhonghua Yi Xue Za Zhi pmid:26814103
Kaieda S et al. Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis. 2015 Mod Rheumatol pmid:24252010
Ichimaru N et al. Risk factors and incidence for lipid abnormalities in kidney transplant patients. 2015 Transplant. Proc. pmid:25891708
Lim EJ et al. Effect of Immunosuppressive Agents on Hepatocyte Apoptosis Post-Liver Transplantation. 2015 PLoS ONE pmid:26390404
Shu WY et al. Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population. 2015 Acta Pharmacol. Sin. pmid:25891088
Soto GAC et al. Dose increase needed in most cystic fibrosis lung transplantation patients when changing from twice- to once-daily tacrolimus oral administration. 2015 Eur. J. Clin. Pharmacol. pmid:25953736
Rojas L et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. 2015 Pharmacogenomics J. pmid:25201288
Ding L et al. Clinical Immunosuppressants Inhibit Inflammatory, Proliferative, and Reprogramming Potential, But Not Angiogenesis of Human Pancreatic Duct Cells. 2015 Cell Transplant pmid:25198311
Daunton A et al. A cutaneous presentation of a common condition. 2015 BMJ pmid:26681202
Yang SS et al. A single center, open-label, randomized pilot study to evaluate the safety and efficacy of tacrolimus modified release, Advagraf, versus tacrolimus twice daily, Prograf, in stable renal recipients (single). 2015 Transplant. Proc. pmid:25891697
Ã…berg F et al. Asymptomatic De Novo Inflammatory Bowel Disease Late After Liver Transplantation for Primary Sclerosing Cholangitis: A Case Report. 2015 Transplant. Proc. pmid:26680092
Rojanathammanee L et al. Attenuation of microglial activation in a mouse model of Alzheimer's disease via NFAT inhibition. 2015 J Neuroinflammation pmid:25889879
Hempen CM et al. Hematocrit-independent recovery of immunosuppressants from DBS using heated flow-through desorption. 2015 Bioanalysis pmid:26327182
Rajaganapathy BR et al. Intravesical Liposomal Tacrolimus Protects against Radiation Cystitis Induced by 3-Beam Targeted Bladder Radiation. 2015 J. Urol. pmid:25839382
Furlan SN et al. Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. 2015 Sci Transl Med pmid:26606970
Nagashima T and Minota S Comment on: The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. 2015 Rheumatology (Oxford) pmid:25832615
Vollmar J et al. Efficacy and safety of a conversion from the original tacrolimus and mycophenolate mofetil to the generics Tacpan and Mowel after liver transplantation. 2015 Drug Des Devel Ther pmid:26604701
Yasuda S et al. Comment on: The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis: reply. 2015 Rheumatology (Oxford) pmid:25832614
Eichenfield DZ and Eichenfield LF Pimecrolimus is safe and effective in treating atopic dermatitis. 2015 J. Pediatr. pmid:26603713
Wang YY et al. Biochemical characterization of a malonyl-specific acyltransferase domain of FK506 biosynthetic polyketide synthase. 2015 Protein Pept. Lett. pmid:25267255
Adotama P et al. Patient satisfaction with different treatment modalities for vitiligo. 2015 J. Am. Acad. Dermatol. pmid:25773415
Cendales L et al. Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report. 2015 Am. J. Transplant. pmid:25773260
Mahajan R et al. Co-localization of agminated congenital melanocytic nevi with vitiligo vulgaris: an unusual presentation. 2015 Int. J. Dermatol. pmid:25039486
Zitelli K et al. Eosinophilic folliculitis occurring after stem cell transplant for acute lymphoblastic leukemia: a case report and review. 2015 Int. J. Dermatol. pmid:25039354
Yokoyama Y et al. Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis. 2015 Mod Rheumatol pmid:25775144
Asrani SK and O'Leary JG Can one pill a day keep rejection away? 2015 Am. J. Transplant. pmid:25703394
Guethoff S et al. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results. 2015 J. Heart Lung Transplant. pmid:25701373
Pensi D et al. An UPLC-MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in peripheral blood mononuclear cells. 2015 J Pharm Biomed Anal pmid:25698619
Kim M et al. Nail lichen striatus: report of seven cases and review of the literature. 2015 Int. J. Dermatol. pmid:26474189
Cen J et al. The new immunosuppressant, isogarcinol, binds directly to its target enzyme calcineurin, unlike cyclosporin A and tacrolimus. 2015 Biochimie pmid:25701551
Mizokami D et al. Tacrolimus prevents laryngotracheal stenosis in an acute-injury rat model. 2015 Laryngoscope pmid:25647147
Ferjani H et al. Tacrolimus and mycophenolate mofetil associations: Induction of oxidative stress or antioxidant effect? 2015 Hum Exp Toxicol pmid:25645822
Rodríguez-Perálvarez M et al. Everolimus is safe within the first month after liver transplantation. 2015 Transpl. Immunol. pmid:26392195
Knops N et al. The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells. 2015 Mol. Pharm. pmid:25590378
Pallet N et al. Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. 2015 Am. J. Transplant. pmid:25588704
Ge Y et al. The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. 2015 Clin. Rheumatol. pmid:26328518
Demir T et al. Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy. 2015 Transplant. Proc. pmid:26093731
Schaap MM et al. A novel toxicogenomics-based approach to categorize (non-)genotoxic carcinogens. 2015 Arch. Toxicol. pmid:25270620
Yoo MC et al. Steroid-free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients. 2015 Transplantation pmid:25539464
Offer K et al. Efficacy of tacrolimus/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation. 2015 Biol. Blood Marrow Transplant. pmid:25536217
Ramachandran R et al. Role of Tacrolimus only therapy in modified Ponticelli regimen resistant idiopathic membranous glomerulonephritis. 2015 Nephrology (Carlton) pmid:25535867
Aikawa Y et al. Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells. 2015 Cancer Sci. pmid:25529853
Kim SH et al. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients. 2015 HBPD INT pmid:26256081
Clift DE et al. Effects of embryonic cyclosporine exposures on brain development and behavior. 2015 Behav. Brain Res. pmid:25591474
Joshi S et al. Phosphatase inhibition prevents the activity-dependent trafficking of GABAA receptors during status epilepticus in the young animal. 2015 Epilepsia pmid:26248944
Duvoux C et al. Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection. 2015 Ann. Transplant. pmid:25588713
Hoerning A et al. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity. 2015 Transplantation pmid:25099702
Valke LL et al. Soluble CD30 does not predict late acute rejection or safe tapering of immunosuppression in renal transplantation. 2015 Transpl. Immunol. pmid:25446808
Spiekerkoetter E et al. Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. 2015 Am. J. Respir. Crit. Care Med. pmid:26177174
Mandelbrot DA et al. Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus. 2015 Am. J. Transplant. pmid:26176342
Regelmann MO et al. New-onset diabetes mellitus after pediatric liver transplantation. 2015 Pediatr Transplant pmid:26032592
Guo CL et al. Efficacy of Topical Tacrolimus for Erosive Oral Lichen Planus: A Meta-analysis. 2015 Chin. Med. Sci. J. pmid:26960301